Insider Selling: Alphatec (NASDAQ:ATEC) CEO Sells 100,000 Shares of Stock

Key Points

• Alphatec CEO Patrick Miles sold 100,000 shares at an average price of $13.96 for a total of $1.4 million, decreasing his ownership by 1.80% to 5,464,078 shares.
• Alphatec's stock price recently traded up 1.5% to $13.96, with a market cap of $2.07 billion and analysts forecasting an average target price of $18.50.
• Institutional investors control 66.35% of Alphatec's stock, with significant recent buying activity from firms like GAMMA Investing LLC and Osterweis Capital Management Inc.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) CEO Patrick Miles sold 100,000 shares of Alphatec stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $13.96, for a total transaction of $1,396,000.00. Following the sale, the chief executive officer directly owned 5,464,078 shares of the company's stock, valued at $76,278,528.88. This represents a 1.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Tuesday, September 2nd, Patrick Miles sold 300,000 shares of Alphatec stock. The shares were sold at an average price of $15.73, for a total transaction of $4,719,000.00.

Alphatec Trading Up 1.5%

Shares of Alphatec stock traded up $0.20 on Friday, hitting $13.96. 1,475,066 shares of the company traded hands, compared to its average volume of 1,765,950. The company has a market cap of $2.07 billion, a PE ratio of -12.35 and a beta of 1.05. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $16.70. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The stock's 50 day moving average price is $15.04 and its 200-day moving average price is $12.52.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. During the same period in the previous year, the company posted ($0.29) earnings per share. The business's revenue for the quarter was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Alphatec in a report on Saturday, September 27th. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday, June 16th. Barclays restated an "overweight" rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Finally, Wall Street Zen lowered shares of Alphatec from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Alphatec currently has an average rating of "Moderate Buy" and an average target price of $18.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Alphatec by 38,433.3% during the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after purchasing an additional 2,306 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Alphatec in the second quarter worth $37,000. Larson Financial Group LLC acquired a new stake in shares of Alphatec in the first quarter worth $54,000. Nisa Investment Advisors LLC lifted its stake in shares of Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after buying an additional 1,045 shares during the last quarter. Finally, Segment Wealth Management LLC acquired a new stake in shares of Alphatec in the first quarter worth $101,000. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.